Electromed (ELMD) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Electromed (ELMD) has outperformed TriSalus Life Sciences (TLSI) over the past year, gaining 10.7% versus a loss of 14.8%. Over five years, ELMD leads with a +153.0% price change compared with -58.3% for TLSI. TriSalus Life Sciences is the larger company by market cap ($250.0 million vs $229.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELMD | TLSI |
|---|---|---|
| Share price | $27.69 | $4.06 |
| Market cap | $229.47M | $249.99M |
| 1-day change | -0.40% | -1.69% |
| YTD return | -4.53% | -40.83% |
| 1-year return | +10.67% | -14.85% |
| 5-year return | +152.96% | -58.28% |
| P/E ratio (TTM) | 21.30 | — |
| Forward P/E | 45.39 | — |
| EPS (TTM) | $1.30 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $47.40 | $7.95 |
| 52-week low | $23.01 | $2.20 |
| Distance from 52-week high | -41.58% | -48.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +75.15% | +156.16% |
| Average volume | 104.86K | 275.38K |
| Shares outstanding | 8.29M | 61.57M |
| Employees | 195 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELMD has outperformed TLSI by 25.5 percentage points over the past year.
About Electromed
ELMD stock →Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 195 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
ELMD vs TLSI FAQ
Which is bigger, Electromed or TriSalus Life Sciences?
TriSalus Life Sciences (TLSI) is larger, with a market capitalization of $249.99M compared with $229.47M for Electromed (ELMD).
Which stock has performed better over the past year, ELMD or TLSI?
ELMD returned +10.67% over the past 12 months, compared with -14.85% for TLSI (price return, excluding dividends). Past performance does not predict future results.
Are Electromed and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for Electromed and Medical Specialities for TriSalus Life Sciences.